Luiz Maurino Abreu1,2. 1. Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ - Brazil. 2. Estimulocor - Avaliação Clinica e Cardiológica, Rio de Janeiro, RJ - Brazil.
Before the 80’s, the treatment of patients with ST-segment
elevation myocardial infarction (STEMI) had as main goals the control of
pain, arrhythmia and reduction of cardiac work, aiming to limit the extent of myocardial
necrosis. These measures were partially effective, but the morbidity and mortality of
acute myocardial infarction (AMI) remained high.[1]From the findings of Dewood,[2]
angiographically showing the presence of coronary occlusion by a thrombus in the culprit
artery of the STEMI, strategies of reperfusion have emerged both thrombolytic therapy
and primary percutaneous transluminal coronary angioplasty (PCI). The treatment of STEMI
changes from contemplation to intervention.About 50 years ago, Eugene Braunwald proposed a revolutionary hypothesis: time is muscle.
It was demonstrated that the severity and extent of myocardial ischemic injury resulting
from coronary occlusion could be radically altered by an adequate intervention as late
as 3 hours after the coronary occlusion.[3]The best strategy for obtaining coronary reperfusion has been a constant topic of
discussion over the last decades, essentially harmed by the mistaken competitive
analysis between the possibilities of getting vessel opening. Most of the time it
ignores the already very well defined and clear in the World guidelines; the best
strategy is that it is available within well-established deadlines, being indifferent in
the first 2 hours of pain.In a publication by Balk et al.,[4] in
this edition, the authors, in a retrospective analysis of a database, comparatively
analyzed the total ischemia times among patients undergoing primary PCI transferred from
other hospitals (Group A = 406) compared to those who sought the service spontaneously
(Group B = 215).Even if you consider this is a retrospective study with database information, there are
very important potential biases. Among these, it was highlighted that 292 patients with
electrocardiogram (ECG) tracings with ST-segment elevation were not transferred or were
not included in the database. How many of these would have undergone thrombolysis at the
site, transferred to another center, or died while waiting? Were they the most
serious?The subject is of great relevance and the global guidelines establish that it adopts the
beneficial strategy within the limit window of transfer to primary PCI of at most 120
minutes.[5]-[7] In the article there is no report
regarding thrombolysis in the first place of care. The average time delay for all
patients in the study was 334 minutes. The average duration of symptoms of the patients
transferred with emergency medical contact via the Health Department (Group A) was 385
minutes, with a delay due to the transport of 147 minutes. The average duration of
symptoms of patients in group B was 307 minutes, reflecting real-world values far from
those described in clinical trials.Several non-PCI-capable hospitals are transferring patients with STEMI to a supposed
primary PCI without a transport protocol that ensures timely time. The medical act is
transferred to another institution and many patients come into the sad statistic of
"lost chance" of reperfusion, in which many do not receive and others are treated
outside the ideal time window for the best result, a fact found in the world records in
which Brazil collaborates.[8]The decision of the best strategy at the first place of care, in which the limitations of
treatment and delays in the transfer were respected, had momentum with the technology
for sending ECG tracings and teleconsulting. There are examples of success in the world
and in Brazil[9]-[13] that demonstrated a reduction in
mortality and greater preservation of myocardium in pre-hospital reperfusion by
emphasizing the organisation of a pre-established regional network for fast transfers
allowing the choice of the best treatment.The pharmaco-invasive strategy comes as a proposal for situations where there is no
guarantee of adequate transfer times and for the period outside the routine hours of the
referral center for primary angioplasty. It has as great merit to offer the two
therapies to the patient. Those without time for adequate transference would receive the
thrombolytic therapy in the first place of care, following a pre-established protocol,
and with more time would be transferred to PCI-capable center to complement the
treatment with the approach of guilty artery. The STREAM[14] study demonstrated benefit and safety being this
strategy adopted by the last European guideline.[15]I agree with the authors' conclusion that their results may serve as an aid to health
system managers to identify opportunities to improve but as a whole. In primary care,
identifying risk groups, promoting prevention and educating for early recognition of
anginous pain; In the first care sites adopt myocardial infarction protocols, when
necessary with teleconsultancy, with the strategy that respects the deadlines and
clinical profile, with a transfer structure (EMS) for transfer to PCI-capable centre for
the most serious cases, to rescue intervention, and for therapeutic complementation in
the pharmaco-invasive line. It would be the Unified National Health System (SUS) full.
The winnings will be all.The myocardium thanks.
Authors: Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao; Jeffrey L Anderson; Alice K Jacobs; Jonathan L Halperin; Nancy M Albert; Ralph G Brindis; Mark A Creager; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; Frederick G Kushner; E Magnus Ohman; William G Stevenson; Clyde W Yancy Journal: Circulation Date: 2012-12-17 Impact factor: 29.690
Authors: Cynthia M Westerhout; Eric Bonnefoy; Robert C Welsh; Philippe Gabriel Steg; Florent Boutitie; Paul W Armstrong Journal: Am Heart J Date: 2011-02 Impact factor: 4.749
Authors: Antonio Luiz P Ribeiro; Maria Beatriz Alkmim; Clareci Silva Cardoso; Gláucio Galeno R Carvalho; Waleska Teixeira Caiaffa; Monica Viegas Andrade; Daniel Ferreira da Cunha; Andre Pires Antunes; Adélson Geraldo de A Resende; Elmiro Santos Resende Journal: Arq Bras Cardiol Date: 2010-06-11 Impact factor: 2.000
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Ana Christina Vellozo Caluza; Adriano H Barbosa; Iran Gonçalves; Carlos Alexandre L de Oliveira; Lívia Nascimento de Matos; Claus Zeefried; Antonio Célio C Moreno; Elcio Tarkieltaub; Cláudia Maria R Alves; Antonio Carlos Carvalho Journal: Arq Bras Cardiol Date: 2012-11-09 Impact factor: 2.000
Authors: Paul W Armstrong; Anthony H Gershlick; Patrick Goldstein; Robert Wilcox; Thierry Danays; Yves Lambert; Vitaly Sulimov; Fernando Rosell Ortiz; Miodrag Ostojic; Robert C Welsh; Antonio C Carvalho; John Nanas; Hans-Richard Arntz; Sigrun Halvorsen; Kurt Huber; Stefan Grajek; Claudio Fresco; Erich Bluhmki; Anne Regelin; Katleen Vandenberghe; Kris Bogaerts; Frans Van de Werf Journal: N Engl J Med Date: 2013-03-10 Impact factor: 176.079